| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| 100g |
|
||
| Other Sizes |
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
AFTER ORAL DOSING WITH (3)H-AAT FOR 2-4 WK, RADIOACTIVITY WAS FOUND IN NUCLEIC ACIDS & PROTEIN. RADIOACTIVITY COULD NO LONGER BE DETECTED BOUND TO PROTEIN AFTER 28 DAYS, BUT WAS PRESENT IN BOTH RNA & DNA 84 DAYS AFTER SINGLE DOSE OF (3)H-AAT. USING AUTORADIOGRAPHY WITH (3)H-AAT & IMMUNOFLUORESCENCE, CMPD WAS SHOWN TO BE TAKEN UP BY PERIPORTAL AREAS OF LIVER LOBULES. RADIOACTIVITY WAS DISTRIBUTED IN ALL PARTS OF CELLS; HOWEVER, BY FLUORESCENCE MICROSCOPY AAT-SPECIFIC ANTIGEN WAS DETECTED IN CYTOPLASMIC GRANULES & AROUND MEMBRANES OF NUCLEUS & NUCLEOLUS. Metabolism / Metabolites LIVERS OF MICE & RATS DOSED WITH AAT CONTAIN FOUR PREVIOUSLY UNIDENTIFIED CMPD, ONE OF WHICH WAS FOUND LATER TO BE 4,4'-BIS(ORTHO-TOLYLAZO)-2,2'-DIMETHYLAZOBENZENE. BILE OF RATS DOSED WITH AAT CONTAINS N-GLUCURONIDE OF AAT, N-GLUCURONIDE OF CORRESPONDING 2-HYDROXYMETHYL DERIVATIVE (IE, 4-AMINO-2-HYDROXYMETHYL-3'-METHYLAZOBENZENE, SULFATE & GLUCURONIDES OF 4-AMINO-4'-HYDROXYAZOTOLUENE & N-GLUCURONIDE-O-SULFATE OF 4'-HYDROXYAZOTOLUENE). IN RABBITS, PARA-TOLUENEDIAMINE IS FORMED ... . AZO LINKAGE OF AAT IS EASILY REDUCED BY YEAST TO GIVE ORTHO-TOLUIDINE & 2-METHYL-1,4-PHENYLENEDIAMINE ... . [2-methyl-4-(o-tolylazo)phenyl]amine has known human metabolites that include 2'-hydroxymethyl-3-raethyl-4-aminoazoberizene, 4'-hydroxy-o-aminoazotoJuene, and N-hydroxy-oaminoazotohiene. |
|---|---|
| Additional Infomation |
o-Aminoazotoluene can cause cancer according to an independent committee of scientific and health experts.
Reddish-brown to golden crystals; orangish red powder. Odorless. (NTP, 1992) Ortho-Aminoazotoluene is a member of azobenzenes. o-Aminoazotoluene is a synthetic organic azo dye used mainly in experimental research, carcinogenic o-Aminoazotoluene induces hepatomas, lung tumors, bladder tumors, and lung hemangioendotheliomas in animals when administered in the diet. (NCI04) An azo dye with carcinogenic properties. Mechanism of Action Increase in the chemical carcinogenicity of aromatic amines due to the presence of methyl groups and aromatic rings is examined. Based on the multistage process of carcinogenesis, data indicate that methyl groups and aromatic amines convert initiators into complete carcinogens. Experiments on rats with aromatic amines show that o-aminoazotoluene and 4-dimethylaminobenzene induce liver tumors. 4-Aminobenzene, considered a tumor initiator, also induces liver tumors in rats. The methyl groups are specifically active; 4-diethylaminobenzene is not carcinogenic whereas 4-dimethylaminobenzene is. Several studies with the aromatic hydrocarbons phenanthrene, chrysene, and benz(a)anthracene show them to be either noncarcinogenic, weakly carcinogenic, or tumor initiators. The methyl derivatives trimethylphenanthrene and 1,2,3,4-tetramethylphenanthrene are weak but not positive skin carcinogens in mice. 7,12-Dimethylbenz(a)anthracene is a very potent tumor promoter. Benzene rings also contribute to the carcinogenic process. It was concluded that in many cases the increase in carcinogenic activity after methyl groups are introduced into the molecule is due to tumor promoting rather than initiating activity. |
| Molecular Formula |
C14H15N3
|
|---|---|
| Molecular Weight |
225.29
|
| Exact Mass |
225.127
|
| CAS # |
97-56-3
|
| PubChem CID |
7340
|
| Appearance |
GOLDEN CRYSTALS
REDDISH-BROWN TO YELLOW CRYSTALS YELLOW LEAVES FROM ALCOHOL |
| Density |
1.09 g/cm3
|
| Boiling Point |
407.7ºC at 760 mmHg
|
| Melting Point |
101-102 °C
|
| Flash Point |
200.4ºC
|
| Index of Refraction |
1.571
|
| LogP |
4.882
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
264
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N(C1C=C(C)C(N)=CC=1)=NC1C(C)=CC=CC=1
|
| InChi Key |
PFRYFZZSECNQOL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H15N3/c1-10-5-3-4-6-14(10)17-16-12-7-8-13(15)11(2)9-12/h3-9H,15H2,1-2H3
|
| Chemical Name |
2-methyl-4-[(2-methylphenyl)diazenyl]aniline
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4387 mL | 22.1936 mL | 44.3872 mL | |
| 5 mM | 0.8877 mL | 4.4387 mL | 8.8774 mL | |
| 10 mM | 0.4439 mL | 2.2194 mL | 4.4387 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
